Table 1. Baseline clinical characteristics.
| ICM | DCM | ||
| Clinical parameter | (n = 32) | (n = 42) | p |
| Age, y | 65±9 | 48±12 | <0.0001 |
| Male sex, n (%) | 25 (78) | 34 (81) | 0.78 |
| LVEF, % | 32±7 | 28±9 | 0.06 |
| Beta-blockers, n (%) | 31 (97) | 41 (98) | 0.90 |
| ACE inhibitors/ARB, n (%) | 32 (100) | 41 (98) | 0.60 |
| Spironolactone, n (%) | 22 (69) | 35 (83) | 0.16 |
| Digoxin, n (%) | 6 (19) | 40 (95) | <0.0001 |
| Diuretics, n (%) | 30 (93) | 33 (79) | 0.07 |
| Amiodarone, n (%) | 2 (6) | 2 (5) | 0.78 |
| Positive PVS, n (%) | 13 (41) | 9 (21) | 0.07 |
| ICD implantation (post MAP), n (%) | 19 (59%) | 4 (10%) | <0.0001 |
ACE = angiotensin-converting enzyme, ARB = angiotensin-receptor blocker, ICD = implantable cardioverter-defibrillator, MAP = monophasic action potential recording, PVS = programmed ventricular stimulation.